Recent Patents on Novel MCH1 Receptor Antagonists as Potential Anti-Obesity Drugs
Katalin K. Szalai, Gyula Beke, Janos Eles, Tamas Kitka, Peter Kovacs, Jozsef Nagy, Sandor Farkas and Andras BorosAffiliation:
Gyomro i u. 24, 1103 Budapest, Hungary.
AbstractToday, the ‘obesity pandemic’ is one of the biggest health issues around the world. Melanin-concentrating hormone (MCH), a hypothalamic neuropeptide, is one of the most potent, central stimulators of feeding and it also attenuates energy expenditure. Inhibitions of the MCH receptor, the melanin-concentrating hormone receptor-1 (MCHR1), has attracted considerable attention as a potential anti-obesity drug, during the last decade. Now, there are a large number of MCHR1 antagonists, pharmacological tools and clinical drug candidates that can provide clues to develop new structures with high potency and good pharmacokinetic profile. The function of MCHR1 in energy homeostasis, obesity, metabolic syndrome, mood disorders and inflammatory bowel disease is discussed. Relevant clinical trials and patent background information of the MCHR1 antagonists over the last 4 years are also reviewed.
Clinical trial, inflammatory bowel disease, melanin-concentrating hormone receptor-1 (MCHR1), mood disorder, obesity, patents.
Purchase Online Order Reprints Order Eprints Rights and Permissions